February 1, 2021 (Cranbury, NJ): The Cholangiocarcinoma Foundation (CCF) designated The Lynx Group (TLG) as a “Trusted Partner,” 1 of only 4 organizations globally. A CCF “Trusted Partner” shares the CCF mission: to find a cure and improve the quality of life for those affected by cholangiocarcinoma (CCA). These 4 esteemed partners are fundamental to the Foundation’s growth and ability to provide high-quality programs and services to the CCA community.
The Lynx Group’s designation is based on one of CCF’s core values: the patient is first in everything we do. As a global strategic medical communications and education company, TLG strives to develop and deliver contemporary educational information for all stakeholders in the healthcare ecosystem. Working together with CCF on the Cholangiocarcinoma Summit, CCA News, and Conquering Cholangiocarcinoma has allowed both organizations to achieve their shared goal of improving the lives of CCA patients and caregivers. This specific partnership has significantly increased the impact of educational outreach and built relationships with key stakeholders within the CCA ecosystem. This is important because the speed at which the science of CCA is moving, immediate and broad dissemination of information is crucial to the care of the patient.
“Partnerships are at the heart of the way we work. The relationships we build with our partners allow us to leverage resources, extend our reach in all aspects, and widen our work’s impact. It is important for us to know that our partners have shared values, among other important factors. We are very grateful for the excellent work our partners have helped accomplish for this community,” said Stacie Lindsey, CCF Founder and CEO.
“It is a sincere honor to be recognized as a trusted partner of the Cholangiocarcinoma Foundation,” said Nick Englezos, Executive Vice President of The Lynx Group and Publisher of CCA News and CONQUER magazine. “CCF’s contribution to CCA News and CONQUER: the patient voice has added tremendous value for healthcare providers, patients, caregivers, and family members of those with cholangiocarcinoma. As a Steering Committee member of the CCA Summit, CCF has been instrumental in identifying faculty and topics for the Summit, which has elevated our ability to impact the CCA community.”
Cholangiocarcinoma, a highly lethal rare cancer with poor prognosis, arises from the bile ducts in the liver. With approximately 10,000 cases a year being diagnosed in the United States, cholangiocarcinoma is the second most common primary liver cancer in the world. It is often diagnosed at advanced stages when treatment is only minimally effective, emphasizing the imminent need for novel therapies.
About Amplity Health
Amplity Health proudly serves as co-founder and association management company of the Academy of Oncology Nurse & Patient Navigators (AONN+) and the Association for Value-Based Cancer Care (AVBCC).
The true partner of global healthcare companies, Amplity Health continually challenges the boundaries of medical and commercial strategies to accelerate the approval and launch of new drugs to improve the lives of patients. We are proud of our inclusive culture and our EPIIC values. Amplity has the expertise, global infrastructure, and data-driven insights to help clients overcome their medical and commercial challenges.
Amplity’s wide-ranging capabilities include clinical and medical outsourced teams; clinical and medical capability development; companion diagnostic and precision medicine solutions; medical communications; expert engagement; remote and field solutions for patients, payers, and physicians; and strategic and access consulting. Amplity’s one-of-a-kind Insights database offers clients a detailed view into patient–provider interactions and provider treatment rationale not found through any other provider.
Amplity Health is a portfolio company of Altamont Capital Partners.
About CCA News
CCA News is an important new publication highlighting the latest research and development in cholangiocarcinoma (CCA). It is a focused publication on biliary tract cancers. This journal reviews the latest clinical research in CCA and biliary tract cancers based on the peer-reviewed literature, oncology meetings, and updates on developments in new drugs.
About the CCA Summit
The CCA Summit focuses on the epidemiology, pathology, translational/basic science, and clinical research impacting the management of patients with CCA. Viewpoints will be heard from medical and surgical oncologists, interventional radiologists, gastroenterologists, and pathologists regarding unmet needs in the treatment of patients with CCA, and the latest approaches to medical and surgical treatment options will be examined. In addition to a deep dive into CCA, gallbladder and biliary cancers will also be assessed.
About the Cholangiocarcinoma Foundation
Founded in 2006, the Cholangiocarcinoma Foundation (CCF) is a global 501(c)(3) nonprofit organization whose mission is to find a cure and improve the quality of life for those affected by bile duct cancer. CCF supports basic and translational research and raises awareness in the cholangiocarcinoma community through advocacy, education, collaboration, and research.
CONQUER: the patient voice™
CONQUER magazine is the Academy of Oncology Nurse & Patient Navigators (AONN+) premier forum for patients with cancer. CONQUER features articles written by and for patients with cancer, survivors, nurse navigators, and other oncology team members. This magazine addresses the issues that patients, their family members, and caregivers face every day in an easy-to-read format. Issues include interviews with patients with cancer, information on access to care, and articles on lifestyle topics such as nutrition, stress management, personal finance, and legal and employer issues. CONQUER also features patient stories that are nominated for the AONN+ Hero of Hope™ award, which is presented at the AONN+ Annual Conference. All stories are compiled in a special issue of CONQUER at the end of the year.